Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study. [PDF]
Ishimoto K +18 more
europepmc +1 more source
SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer. [PDF]
Zhu Z, Shen Y, He X, Zhou M.
europepmc +1 more source
Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report. [PDF]
Numata Y +9 more
europepmc +1 more source
Enzalutamide-associated acute exacerbation of interstitial lung abnormality: a case report. [PDF]
Meiduo S +6 more
europepmc +1 more source
Exploring Radiographic Progression-Free Survival in Diverse Subgroups of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Efficacy of Abiraterone and Enzalutamide. [PDF]
Özmen A, Tural D.
europepmc +1 more source
Docosahexaenoic Acid Enhances the Cytotoxic Effects of Enzalutamide and the PARP Inhibitor in Castration-Resistant Prostate Cancer Cell Lines. [PDF]
da Silva ADT +4 more
europepmc +1 more source
Global management of drug-drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist. [PDF]
Valsecchi AA +16 more
europepmc +1 more source
Apalutamide-induced prostate-specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review). [PDF]
N S +8 more
europepmc +1 more source

